-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EsPcmiMXBHqyD5P6LVnsQW3/G8En+udM6/faRQ+fkoag428BH/Lt99kM2/QbD3dq KGTYaMJEdQ7lhDta2NgsKQ== 0001048477-01-000008.txt : 20010205 0001048477-01-000008.hdr.sgml : 20010205 ACCESSION NUMBER: 0001048477-01-000008 CONFORMED SUBMISSION TYPE: 424B2 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20010131 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B2 SEC ACT: SEC FILE NUMBER: 333-48800 FILM NUMBER: 1520193 BUSINESS ADDRESS: STREET 1: 11 PIMENTEL COURT CITY: NOVATO STATE: CA ZIP: 94949 MAIL ADDRESS: STREET 1: 11 PIMENTEL COURT STREET 2: 11 PIMENTEL COURT CITY: NOVATO STATE: CA ZIP: 94949 424B2 1 0001.txt BIOMARIN PHARMACEUTICAL INC. Rule 424(b)(2) Prospectus Supplement Registration No. 333-48800 PROSPECTUS SUPPLEMENT NO. 1 TO PROSPECTUS DATED January 29, 2001 101,523 Shares BioMarin Pharmaceutical Inc. Common Stock --------------------- This Prospectus Supplement supplements information contained in that certain Prospectus of BioMarin Pharmaceutical Inc. dated January 29, 2001 relating to the potential sale and issuance from time to time of up to 4,000,000 shares of BioMarin common stock. This Prospectus Supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any amendments or supplements thereto. This Prospectus Supplement is incorporated by reference into the Prospectus. You should read this Prospectus Supplement and the accompanying Prospectus carefully before you invest. Both documents contain information you should consider carefully before making your investment decision. See "Risk Factors" beginning on page 3 of the Prospectus to read about risks that you should consider before buying shares of our common stock. -------------------------- You should rely only on the information provided or incorporated by reference in this Prospectus Supplement and the Prospectus. We have not authorized anyone else to provide you with different information. You should not assume that the information in this Prospectus Supplement is accurate as of any date other than the date on the front of this Prospectus Supplement. -------------------------- NEITHER THE SECURITIES EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. -------------------------- The date of this Prospectus Supplement is January 31, 2001 TABLE OF CONTENTS PROSPECTUS SUPPLEMENT Plan of Distribution.........................................................S-1 PROSPECTUS Summary........................................................................1 The Offering...................................................................2 Risk Factors...................................................................3 Forward Looking Statements....................................................14 Material Changes to our Company...............................................15 Use of Proceeds...............................................................16 Plan of Distribution..........................................................17 Legal Matters.................................................................18 Experts.......................................................................18 The following information supplements the information set forth in the Prospectus. PLAN OF DISTRIBUTION On February 1, 2001, we will issue and sell 101,523 shares of our common stock to Acqua Wellington North American Equities Fund, Ltd. pursuant to this prospectus supplement. The common stock will be purchased at a negotiated purchase price of $9.85. The purchase price reflects the volume weighted average of the trading prices of our common stock on the Nasdaq National Market calculated on January 25, 2001, less a discount of 6% pursuant to the terms of the common stock purchase agreement entered into between Acqua Wellington and us on January 26, 2001. We will not pay any other compensation in conjunction with the sale of these shares of our common stock. See "Plan of Distribution" beginning on page 17 of the prospectus. -----END PRIVACY-ENHANCED MESSAGE-----